Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCurrent status of the prognostic molecular biomarkers in breast cancer: A systematic reviewThe Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis.
P2860
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@ast
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@en
type
label
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@ast
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@en
prefLabel
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@ast
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@en
P2093
P2860
P356
P1476
Adjuvant epirubicin followed b ...... d phase III NEAT/BR9601 trials
@en
P2093
A-L Vallier
C J Twelves
D A Spooner
E Provenzano
P2860
P2888
P304
P356
10.1038/BJC.2012.370
P407
P577
2012-09-11T00:00:00Z